Tech Company EmpiraMed Boosts Customer Domain Expertise by Hiring 2 Biopharmaceutical Industry Veterans

MAYNARD, Mass., Nov. 6, 2017 /PRNewswire/ -- EmpiraMed, Inc., a leader in the field of patient engagement software to capture Real World Evidence, today announced that two executives were hired who have deep biopharmaceutical industry experience. According to Greg Erman, President & CEO of EmpiraMed, "we started this company by interviewing biopharma stakeholders using a unique 'voice-of-the-customer' methodology, built our technology based completely on unmet customer needs, successfully implemented our software at several large biopharma companies, generated data to prove our clients can boost patient engagement to 3X industry norms, and have now hired two exceptional executives from our own customer market to help guide our growth."

Dan Larson, EmpiraMed's new VP of Clinical Operations, has 20 years of biotech experience in clinical research. Dan oversaw the conduct of clinical trials at AMAG Pharmaceuticals, Deciphera Pharmaceuticals, and AlloCure. Prior to that, he managed clinical trials at Molecular Insight Pharmaceuticals, Averion International Corporation, Bard Electrophysiology, and Biogen. Dan started in industry in data management at Quintiles. He also designed the user interface for the widely acclaimed EDC software, InForm, while at Phase Forward. Dan graduated summa cum laude from Boston University's school of Biomedical Laboratory and Clinical Sciences.

Paul Krysiak has been appointed EmpiraMed's VP of Sales & Business Development. Most recently, Paul was the CEO of Seva Therapeutics, an innovative pre-clinical oncology company. His previous experience includes serving in executive commercial, marketing, and sales roles at 3G Therapeutics, Ceerdis Corporation, BioMarin Pharmaceuticals, Genzyme Corporation, and Merck.  While in Europe, Paul was also the Co-Founder and President of the Orphan Drug Manufacturers Representatives Association. Paul obtained an MSc. in Molecular Physiology from the University of Western Ontario and a BSc. in both Biomedical Sciences and Biochemistry from the University of Guelph.

According to Paul Krysiak, "I am very excited to join EmpiraMed. EmpiraMed's strong leadership, combined with a flexible and robust technology platform, offers a unique set of advantages to access real world evidence (RWE), execute virtual trials, and much more. In fact, I believe that EmpiraMed's offering is the best solution available today."

Dan Larson adds, "I have run clinical operations for many years in the biopharmaceutical industry and was immediately attracted to EmpiraMed's technical innovations and proven successes.  EmpiraMed clearly has developed a model that can disrupt the industry by offering biopharmaceutical companies more cost-effective solutions to capture real world patient experience. I hope to apply my customer domain expertise to help EmpiraMed's clients accelerate approvals of new therapies and indications as well as improve market access and patient outcomes."

About EmpiraMed
EmpiraMed has developed a patient engagement software platform to capture Real World Evidence and to execute Outcomes Based Contracts and Quality Improvement Intervention Programs.  Our customers have included Merck Sharp & Dohme, Biogen, Janssen, Sanofi, United Therapeutics, and Teva.

Please see our full press release at:  http://www.empiramed.com/press/New_Executive_Hires_Press_Release_11-6-2017.pdf

SOURCE EmpiraMed, Inc.

Related Links

http://www.EmpiraMed.com